Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

NASDAQ:KRYS

Overview | Financials
Company Name Krystal Biotech, Inc.
Symbol KRYS
Currency USD
Price 161.3
Market Cap 4,639,068,650
Dividend Yield 0%
52-week-range 107.5 - 219.34
Industry Biotechnology
Sector Healthcare
CEO Mr. Krish S. Krishnan M.B.A., M.S.
Website https://www.krystalbio.com

An error occurred while fetching data.

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved

Related Stocks

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

3.19 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

21.1 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

30.725 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

39.98 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

123.02 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

117.26 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

13 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

4.8 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

40 USD

Financials

Numbers are in millions USD

Numbers are in millions USD